Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AEMD… 3 daily gap dowNs, way below the lower keltner line here… GidDy uP AEMD
https://schrts.co/TxGGNVAi
AEMD creeping uP after hours… Still Cheapies…
Even lower now.
Will it grow legs after 9:30
Most med techs don’t
Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma
HAS AMED R/S YET ?????
AEMD
Aethlon Medical Inc
0.331
-0.0156 (-4.50%)
Volume: 77,709
Day Range: 0.3213 - 0.3466
Last Trade Time: 7:52:36 PM EDT
Ahhh the ole R/S to purge the investors. I kissed this one goodbye a long time ago. This will be my 3rd R/S. Nothing left of this garbage I've had stinkin up my portfolio since 2014. This is what they do in pennyland. Per the proxy: Reverse stock split of our common stock at a ratio in the range of 1-for-8 to 1-for-12, with such ratio to be determined in the discretion of our Board of Directors and with such reverse stock split to be effected at such time and date as determined by our Board of Directors in its sole discretion.
AEMD
Aethlon Medical Inc
0.436
0.0016 (0.37%)
Volume: 87,927
Day Range: 0.4201 - 0.4599
Bid: 0.4359
Ask: 0.4499
Last Trade Time: 7:30:44 PM EDT
Total Trades: 258
Gathering steam. Yes, $AEMD$
yes AEMD
Aethlon Medical Inc
0.4344
-0.0159 (-3.53%)
Volume: 217,584
Day Range: 0.432 - 0.46
Bid: 0.4562
Ask: 0.458
Last Trade Time: 4:36:56 PM EDT
Total Trades: 384
AEMD
Aethlon Medical Inc
0.418
-0.007 (-1.65%)
Volume: 761,142
Day Range: 0.40 - 0.4375
Last Trade Time: 7:54:26 PM EDT
AEMD
Aethlon Medical Inc
0.418
-0.007 (-1.65%)
Volume: 761,142
Day Range: 0.40 - 0.4375
Bid: 0.417
Ask: 0.4349
Last Trade Time: 7:54:26 PM EDT
Total Trades: 1,490
close .425 according to my fidlelity.
bought a few more a tad higher than close. Nice volume. Glad though I added a few days ago as well.
yes, creeping <> AEMD
Aethlon Medical Inc
0.4101
0.0701 (20.62%)
Volume: 8,100,795
Day Range: 0.38 - 0.50
Bid: 0.4101
Ask: 0.417
Last Trade Time: 7:58:04 PM EDT
Total Trades: 10,320
Potential here is quite large and transformative in more than a few areas. fda seems quite cooperative now too which is quite unusual.
Jun-30-23 12:42PM
Aethlon Medical, Inc. (NASDAQ:AEMD) Q4 2023 Earnings Call Transcript
(Insider Monkey)
-9.82%
Jun-28-23 04:15PM
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
(PR Newswire)
+7.85%
Jun-22-23 08:01AM
Aethlon Medical to Release Fourth Quarter and Year End Financial Results and Host Conference Call on June 28, 2023
(PR Newswire)
Jun-21-23 08:01AM
Aethlon Medical Announces Investigation of the Hemopurifier® for Use in Organ Transplantation
(PR Newswire)
Jun-14-23 08:01AM
Aethlon Medical to Participate in the Healthcare Virtual Conference Presented by Maxim Group and Hosted by M-Vest
(PR Newswire)
09:13AM
Loading…
Jun-08-23 09:13AM
AEMD: Maximizing R&D Spending to Facilitate Clinical Efforts, Advance Hemopurifier
(Zacks Small Cap Research)
Jun-01-23 03:51PM
Aethlon Medical to Present at the 13th Annual LD Micro Invitational
(PR Newswire)
Aethlon Medical to Release Fourth Quarter and Year End Financial Results and Host Conference Call on June 28, 2023 • PR Newswire (US) • 06/22/2023 12:01:00 PM
Short Interest 0.10M
Shs Float 22.70M
Shs Outstand 22.95M
NEUTRAL <> interesting yet ????? $AEMD 06-18-2020 Aethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients
PR Newswire PR Newswire•June 18, 2020
Allows for enrollment of up to 40 subjects in up to 20 centers
https://finance.yahoo.com/news/aethlon-announces-fda-approval-ide-131900535.html
SAN DIEGO, June 18, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the U.S. Food and Drug Administration (FDA) has approved a
supplement to the Company's existing Investigational Device Exemption (IDE) for the Company's Hemopurifier® in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19 in a new feasibility study.
The feasibility study, which is the device equivalent of a phase 1 trial, will enroll up to 40 subjects at up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19,
be admitted to an intensive care unit (ICU) and will have acute lung injury and/or severe or life threatening disease among other criteria.
The Hemopurifier has previously been tested in patients with hepatitis
C virus (HCV) infection and in one patient with Ebola virus infection.
A laboratory version of the Hemopurifier has also been shown to clear multiple other viruses in vitro including a model version of the
Middle Eastern Respiratory Syndrome (MERS) virus which is a
coronavirus from the same family as the SARS-CoV-2 virus that causes COVID-19.
Timothy C. Rodell, M.D., Chief Executive Officer of Aethlon, stated,
"We believe that the Hemopurifier may have the potential to help severely affected patients with COVID-19.
We believe that clearing circulating virus in these patients, in combination with other supportive measures, could improve outcomes in this deadly disease."
The Hemopurifier is an FDA designated "Breakthrough Device" for the treatment of life-threatening viruses that are not addressed with approved therapies.
The Hemopurifier also holds a Breakthrough Device designation for the treatment of individuals with advanced or metastatic cancer who are
either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease.
About Aethlon Medical, Inc.
Aethlon Medical, Inc. is focused on addressing unmet needs in global health.
The Aethlon Hemopurifier is a clinical-stage device designed to combat cancer and life-threatening viral infections.
Aethlon also owns 80% of Exosome Sciences, Inc., which is focused on
the discovery of exosomal biomarkers to diagnose and monitor cancer
and neurological disease progression. Additional information can be found online at
http://www.AethlonMedical.com and http://www.ExosomeSciences.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially," "appear" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, Aethlon Medical, Inc.'s (the Company) ability to enroll patients and to successfully complete the Early Feasibility Studies in viral diseases and cancer and achieve the endpoints for the study or any future studies with its Hemopurifier or to successfully develop and commercialize the Hemopurifier. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Continue reading
http://ih.advfn.com/stock-market/NASDAQ/aethlon-medical-AEMD/stock-news/82687431/aethlon-announces-fda-approval-of-ide-supplement
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 x3300
Jfrakes@aethlonmedical.com
Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
Cision
Cision
More
View original content:http://www.prnewswire.com/news-releases/aethlon-announces-fda-approval-of-ide-supplement--for-covid-19-patients-301079557.html
NEUTRAL <> interesting yet ????? $AEMD 06-18-2020 Aethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients
PR Newswire PR Newswire•June 18, 2020
Allows for enrollment of up to 40 subjects in up to 20 centers
https://finance.yahoo.com/news/aethlon-announces-fda-approval-ide-131900535.html
SAN DIEGO, June 18, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the U.S. Food and Drug Administration (FDA) has approved a
supplement to the Company's existing Investigational Device Exemption (IDE) for the Company's Hemopurifier® in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19 in a new feasibility study.
The feasibility study, which is the device equivalent of a phase 1 trial, will enroll up to 40 subjects at up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19,
be admitted to an intensive care unit (ICU) and will have acute lung injury and/or severe or life threatening disease among other criteria.
The Hemopurifier has previously been tested in patients with hepatitis
C virus (HCV) infection and in one patient with Ebola virus infection.
A laboratory version of the Hemopurifier has also been shown to clear multiple other viruses in vitro including a model version of the
Middle Eastern Respiratory Syndrome (MERS) virus which is a
coronavirus from the same family as the SARS-CoV-2 virus that causes COVID-19.
Timothy C. Rodell, M.D., Chief Executive Officer of Aethlon, stated,
"We believe that the Hemopurifier may have the potential to help severely affected patients with COVID-19.
We believe that clearing circulating virus in these patients, in combination with other supportive measures, could improve outcomes in this deadly disease."
The Hemopurifier is an FDA designated "Breakthrough Device" for the treatment of life-threatening viruses that are not addressed with approved therapies.
The Hemopurifier also holds a Breakthrough Device designation for the treatment of individuals with advanced or metastatic cancer who are
either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease.
About Aethlon Medical, Inc.
Aethlon Medical, Inc. is focused on addressing unmet needs in global health.
The Aethlon Hemopurifier is a clinical-stage device designed to combat cancer and life-threatening viral infections.
Aethlon also owns 80% of Exosome Sciences, Inc., which is focused on
the discovery of exosomal biomarkers to diagnose and monitor cancer
and neurological disease progression. Additional information can be found online at
http://www.AethlonMedical.com and http://www.ExosomeSciences.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially," "appear" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, Aethlon Medical, Inc.'s (the Company) ability to enroll patients and to successfully complete the Early Feasibility Studies in viral diseases and cancer and achieve the endpoints for the study or any future studies with its Hemopurifier or to successfully develop and commercialize the Hemopurifier. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Continue reading
http://ih.advfn.com/stock-market/NASDAQ/aethlon-medical-AEMD/stock-news/82687431/aethlon-announces-fda-approval-of-ide-supplement
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 x3300
Jfrakes@aethlonmedical.com
Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
Cision
Cision
More
View original content:http://www.prnewswire.com/news-releases/aethlon-announces-fda-approval-of-ide-supplement--for-covid-19-patients-301079557.html
Things are getting much brighter here. 14 Million in the bank and ........
Aethlon Medical Q4 EPS $(0.11) Up From $(0.25) YoY, Sales $574.25K Up From $13.12K YoY
BENZINGA
4:37 PM ET 06/28/2023
Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(0.11) per share. This is a 56 percent increase over losses of $(0.25) per share from the same period last year. The company reported $574.25 thousand in sales this quarter. This is a 4.28K percent increase over sales of $13.12 thousand the same period last year.
AEMD
Aethlon Medical Inc
0.3772
-0.0012 (-0.32%)
Volume: 205,819
Day Range: 0.3728 - 0.38
Last Trade Time: 7:35:14 PM EDT
MAYBE CHANCE FER BIG ONE ????? $AMED
AEMD
Aethlon Medical Inc
0.3092
0.0136 (4.60%)
Volume: 133,425
Day Range: 0.300001 - 0.32
Last Trade Time: 7:10:51 PM EDT
AEMD
Aethlon Medical Inc
0.3092
0.0136 (4.60%)
Volume: 133,425
Day Range: 0.300001 - 0.32
Last Trade Time: 7:10:51 PM EDT
AEMD
Aethlon Medical Inc
0.38
-0.0168 (-4.23%)
Volume: 479,255
Day Range: 0.3601 - 0.40
Last Trade Time: 7:59:20 PM EDT
Choo choo play as they want the chase.
AEMD
mb
I can't find any major news today on AEMD, not even on their website.
IMO : ONE WORD
DUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUMPO !!
BULLSHIT PR.
Followers
|
227
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
18430
|
Created
|
11/19/04
|
Type
|
Free
|
Moderators |
At Aethlon Medical, we are a leading developer of immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses,
the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies.
The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure cloaks these targets from immune detection.
At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc.,
a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases.
Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical,
is focused on the discovery of exosomal biomarker candidates to diagnose and monitor life-threatening diseases.
The proprietary Enzyme-Linked Lectin-Specific Assay (ELLSA™) serves as a platform to isolate exosomal biomarkers from a wide-range of bodily fluids.
In preliminary studies, ELLSA™ demonstrated the ability to isolate exosomes from urine, which resulted in high-sensitivity detection of HIV-infection.
Specific to neurological disorders, Exosome Sciences discovered TauSome™, an exosomal biomarker that may be the first non-invasive candidate to
detect Chronic Traumatic Encephalopathy (CTE) in living individuals. In a study of former National Football League (NFL) players,
TauSome levels were found to be significantly higher as compared to athlete control subjects who participated in non-contact sports.
TauSome levels also correlated with cognitive decline based standardized tests of memory and psychomotor speed. Visit www.exosomesciences.com for additional details.
Time Magazine named the Hemopurifier® a "Top 25 Invention" and a "Remarkable Advance in Healthcare" based on its use in treating Ebola virus.
Emerging pathogens pose a significant threat to mankind. Of the hundreds of viral pathogens known to be infectious to man, only a few are addressed with
proven antiviral drug or vaccine therapies. Beyond the looming threat of bioterrorism, a proliferation of international travel, urban crowding and global warming
is expected to accelerate the emergence of future pandemics. In response, the U.S. Department of Health and Human Services (HHS) has established an initiative
to support platform technology medical countermeasures with broad-spectrum capabilities. Based on preclinical studies and human treatment experiences, the Aethlon Hemopurifier® defines this initiative.
To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV).
In the case of Ebola, a remarkable response to a single administration of Hemopurifier therapy (comatose physician with multiple organ failure at the time), led to
Time Magazine naming the Hemopurifier to be one of the "Top 25 Inventions" as well as one of the "Eleven Most Remarkable Advances in Healthcare."
Beyond human treatment experiences, pre-clinical Hemopurifier studies have validated the broad-spectrum capture of numerous viral threats.
These include: Chikungunya, Dengue and West Nile virus, as well as Vaccinia and Monkey pox, which serve as models for human Smallpox infection.
Specific to pandemic influenza threats, Aethlon has validated the capture of H5N1 avian flu, H1N1 swine flu, and the reconstructed 1918 influenza virus,
which represents a model for the strain of influenza that killed an estimated 50 million victims in 1918 and 1919. In vitro studies of other viral threats are ongoing.
https://coronavirus.jhu.edu/map.html
================================================================================================================================================================================
================================================================================================================================================================================
================================================================================================================================================================================
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |